Treatment with Human Mesenchymal Stem Cells (Remestemcel-L) Is Effective in Pediatric Patients with Refractory Acute Graft Versus Host Disease  by Kurtzberg, Joanne et al.
Figure 1. OS of Unrelated vs Related
Figure 2. OS of BM vs. PBSC
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354S338491
Overall Survival (OS) of Pediatric Patients with Moderate
to Severe Chronic Graft Vs. Host Disease (CGVHD). a Single
Institution Experience
Morris Kletzel 1, Kyle Kauffman 2, Kimberly Powers 3,
Reggie E. Duerst 4, Sonali Chaudhury 5,
Jennifer Schneiderman 4, William T. Tse 6,
Sana Khan Medical Student 7. 1 Northwestern University
Feinberg School of Medicine, Chicago, IL; 2 Lurie Children’s
Hospital of Chicago, Chicago, IL; 3 Hematology/Oncology/Stem
Cell Transplant, Lurie Children’s Hospital of Chicago, Chicago,
IL; 4 Ann & Robert H. Lurie Children’s Hospital of Chicago,
Chicago, IL; 5Hematology/Oncology/Stem Cell Transplantation,
Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago,
IL; 6 Children’s Memorial Research Center, Chicago, IL;
7 Hematology, Oncology, Transplant, Ann & Robert H. Lurie
Children’s Hospital of Chicago, Chicago, IL
CGVHD is a major complication with high morbidity and
mortality post allogeneic hematopoietic cell transplants
(HCT). An IRB approved retrospective review of 338 pediatric
survivors of HCT (>1yr) between 1992-2012 at Lurie Chil-
dren’s Hospital was performed. Forty nine patients met NIH
criteria for moderate to severe CGVHD. Patient characteris-
tics are shown in table 1. The prevalence of CGVHD was 14%.
The median time from transplant to diagnosis of CGVHD was
0.49 (0-9.6) years. Hazard ratios (HR) & 95% CI for OS by Cox
Log rank analysis were: related vs. unrelated donor (2.54, CI
1.11-5.7) Fig 1; BM vs. PBSC (0.33, CI 0.13-0.85) Fig 2; degree
of matching (0.56, CI 0.20-1.5) Fig 3 and Myeloablative con-
ditioning (MCR) vs. Reduced Intensity (RIC) (1.9, CI 0.80-4.8
p¼0.14). The OS at 5 years was 55% and at 10 years 46%. The
major causes of mortality were: CGVHD (6), Infection (9),
Disease progression (2), Cardiac (2), renal failure (1) and
unknown (2). Factors associated with a poorer survival areTable 1
Patient Characteristics
Age (median) 11 + 6.4 y
Gender
M/F 33/16
Ethnicity
Caucasian 31
Hispanic 8
African American 8
Other 2
Diagnosis
Malignancy 40
Other 9
Stem Cell Source
Related 25
Un-related 24
Marrow 10
PBSC 36
UCB 3
CD 34 cell dose (median) 6.7 X106/kg (.26-29)
HLA Matched
Matched 32
1 Antigen Mismatch 13
2 Antigen Mismatch 4
Conditioning Regimen
Myeloablative 34
Reduced intensity 15
Disease Status at transplant
(Malignancy patients)
CR 1 12
CR2 21
CR3 7
CGVHD organ involvement
Moderate 12
Severe 37
Figure 3. OS by Degree of Matchingdegree of matching (2 antigen mismatches), related vs.
unrelated and BM vs. PBSC. We could not ﬁnd a difference in
OS between RIC vs. MCR. The main cause of death was
infection and progression of CGVHD (pulmonary).492
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(aGVHD) causes signiﬁcant morbidity and mortality after
allogeneic hematopoietic stem cell transplantation. Early
clinical trials of therapywith humanmesenchymal stem cells
(hMSCs) in pediatric patients with severe aGVHD, resistant to
multiple immunosuppressive agents, showed promising re-
sults. In this study, we evaluated the risk/beneﬁt proﬁle of
remestemcel-L, an off-the-shelf source of culture expanded
human mesenchymal stem cells, provided by Mesoblast, Inc.
under an expanded access program, as a rescue agent for
treatment-resistant aGVHD in pediatric patients. Children
with grade B-D aGVHD failing steroids and, in most cases,
other immunosuppressive agents were eligible for enroll-
ment. Patients received 8 bi-weekly i.v. infusions of 2  106
hMSCs/kg for 4 weeks, with an additional 4 weekly infusions
after day +28 for patients who achieved either a partial or
mixed response. The enrolled patients compose a very
challenging population with severe disease that was nonre-
sponsive to standard of care. One hundred sixty patients
(median age, 10 years; 60% male; and 61% Caucasian) were
treated in this study. One hundred thirty ﬁve patients (84%)
received unrelated donor transplant. Graft source was bone
marrow in 65 (41%), PBSC in 34 (21%), cord blood in 54 (34%)
and donor leukocyte infusion in 5 (3%). At baseline, the dis-
tribution of aGVHD grades B, C, and D was 19%, 28%, and 53%,
respectively; 81% of the patients had severe aGVHD (grade C
or D). Median duration of aGVHD before enrollment was 28
d (range, 1 to 237), and patients had failed a median of 3
immunosuppressive agents. Organ involvement at baseline
was 89% gastrointestinal (GI), 50% skin, and 29% liver. Sixty-
six patients (41%) had 2 organs involved, and 24 patients
(15%) had all 3 organs involved. The rate of overall response
(complete and partial response) at day +28 was 74% for
aGVHD grade B, 66% for grade C, and 59% for grade D. Overall
response for individual organs at day +28 was 62% for GI, 77%
for skin, and 53% for liver. Collectively, overall response at
day +28 for patients treated for severe refractory aGVHD was
64%, and this response was correlated with statistically sig-
niﬁcant improved survival at day +100 after hMSC infusion.
Patients who responded to therapy by day +28 had a higher
Kaplan-Meier estimated probability of 100-d survival
compared with patients who did not respond (79% vs. 21%;
P < .0001). Substantial numbers of patients beneﬁted from
additional therapy beyond the initial 4 weeks of treatment.
Ninety one patients (57%) received more than 8 infusions,
with 48% of those patients experiencing additional
improvement by day +100. Remestemcel-L infusions were
generally well tolerated, without excessive infusional toxic-
ities or ectopic tissue formation. The results of this study
support the use of remestemcel-L for pediatric patients with
refractory aGVHD.493
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Graft-versus-host-disease (GVHD) is an alloimmune res-
ponse complicating allogeneic hematopoietic stem celltransplantation (allo-HSCT). The development of GVHD is
thought to involve three phases: T cell activation, followed by
proliferation and differentiation of allogeneic T cells into
activated effector cells, and ﬁnally speciﬁc tissue damage. In
the activation phase, donor T cells interact with host APCs,
leading to activation and differentiation toward the effector
pathway and migration of these cells to target tissues
affected during acute GVHD. Although donor T lymphocytes
and recipient antigen presenting cells (APCs) are the pri-
marily mediators of GVHD, the molecular and cellular basis
are not well understood. Thus, the prevention and treatment
of GVHD remains a major challenge. Deoxyribonuclease I
(DNaseI) is an endonuclease that facilitates chromatin
breakdown of apoptotic and necrotic cells. The impaired
activity of DNaseI has been associated with the pathogenesis
of systemic lupus erythematosus (SLE) and inﬂammatory
bowel diseases (IBD). Using the MHC class I and II disparate
model, C57BL/6 (H-2b) to BALB/c (H-2d), our studies
demonstrate that DNaseI treatment can reduce GVHD mor-
tality and morbidity in mice. In comparison to PBS control,
DNaseI-treatedmice showed a lowermortality rate. Within 4
weeks post-transplantation, 80% of DNaseI-treated re-
cipients survived, compared with only 30% of PBS control
mice. Whereas control recipients had severe GVHD in the
skin, intestine, liver, and lung, DNaseI-treated mice exhibited
only mild changes in these organs, reﬂected in their signiﬁ-
cantly lower GVHD scores. Furthermore, we analyzed donor-
derived T cells in mice 7 days post-transplant, and found a
signiﬁcantly lower number of donor-derived CD4+ and CD8+
subsets in the peripheral lymph node (pLN) and Peyer’s
patches (PP) of DNaseI-treated mice compared to that of PBS
control recipients. We further investigated the functional
consequences of DNaseI treatment on inﬂammatory cytokine
production in GVHD mice, and found the frequency of IFN-g
(Th1), IL-17 (Th17) and IL-2 producing donor CD4+ cells in the
spleen was signiﬁcantly reduced in DNaseI-treated mice
compared to PBS control mice. The results have established
the disease-modifying activity of DNaseI in mouse GVHD
model, and thus raise the possibility for using this drug as a
potential new therapeutic intervention.494
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Apoptotic cells infusion (ApoCell, by Enlivex Ltd) is a novel
cellular therapy that was found to be effective in a variety of
mouse models of autoimmune diseases. ApoCell was tested
in humans in addition to cyclosporine and methotrexate, as
prophylaxis of graft-versus-host disease (GVHD) in HLA-
matched myeloablative allogeneic bone marrow trans-
plantation (alloBMT) from a related donor. We conducted a
phase I//IIa clinical trial where 13 patients (median age, 37
years; range, 20-59 years) with advanced hematologic ma-
lignancies that received conventional myeloablation were
